Search results for " Humans"

showing 10 items of 2466 documents

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

2019

Background: Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be effective as initial treatment, but 20% of patients (pts) had relapses. aPCC as short-term prophylaxis to reduce subsequent bleeds is still not clear. Aim: To evaluate whether a short-term prophylaxis with low dose of aPCC can reduce bleeding relapses after initial AHA treatment, maintaining safety. Methods: The FAIR Registry is a retrospective-prospective study started on December 2012, that collected data on all pts with AHA treated with aPCC in 12 Italian Haemophilia Centers. All statistical analyses were carried out in the 5…

Malemedicine.medical_specialtyAcquired haemophilia; Bleeding relapses; Bypassing agents; Prophylaxis; Aged; Female; Hemophilia A; Hemorrhage; Humans; Male; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective StudiesHemorrhage030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineFirst line therapyRecurrenceInternal medicineAcquired haemophiliamedicineHumansInitial treatmentIn patientProspective StudiesProphylaxiActivated prothrombin complex concentrateBypassing agentAgedRetrospective StudiesHematologyProphylaxisbusiness.industryLow doseBleeding relapseHematologymedicine.diseaseRecombinant Proteins030220 oncology & carcinogenesisFemaleBleeding relapsesBypassing agentsbusinessAcquired haemophiliaThrombosis Research
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

2015

Objective.The main objective was to determine the 2-year clinical benefit and safety of etanercept (ETN) in children with the juvenile idiopathic arthritis (JIA) categories of extended oligoarthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).Methods.CLIPPER was a 96-week, phase IIIb, open-label, multicenter study. Patients with eoJIA, ERA, or PsA received ETN 0.8 mg/kg once weekly (50 mg max) for up to 96 weeks. The proportions of patients reaching the JIA American College of Rheumatology (ACR) 30/50/70/90/100 and inactive disease responses at Week 96 were calculated. Adverse events (AE) were collected throughout the study (intention-to-treat sample).Results.…

Malemedicine.medical_specialtyAdolescentEnthesitis-related arthritisImmunologyArthritisJuvenilePsoriaticEtanerceptEtanercept03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRheumatologyInternal medicinemedicineImmunology and AllergyHumans030212 general & internal medicinePreschoolChild030203 arthritis & rheumatologyOligoarthritisbusiness.industryArthritisArthritis PsoriaticClinical trial; Enthesitis-related arthritis; Etanercept; Extended oligoarthritis; Juvenile idiopathic arthritis; Psoriatic arthritis; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Arthritis Psoriatic; Child; Child Preschool; Etanercept; Female; Humans; Male; Treatment OutcomeJuvenile idiopathic arthritismedicine.diseaseRheumatologyPharyngitisArthritis Juvenile3. Good healthSurgeryClinical trialUpper respiratory tract infectionTreatment OutcomePsoriatic arthritisAntirheumatic AgentsChild PreschoolExtended oligoarthritisBronchitisFemalemedicine.symptombusinessmedicine.drugThe Journal of rheumatology
researchProduct

Enuresis Subtypes Based on Nocturnal Hypercalciuria: A Multicenter Study

2003

Purpose: Desmopressin may not be effective for nocturnal enuresis associated with polyuria and hypercalciuria. Nighttime hypercalciuria in an enuretic population from 5 centers and its correlation with nighttime polyuria were verified. Materials and Methods: A total of 450 enuretic patients (278 males, 172 females, mean age 9.7 years) were evaluated with 72-hour micturition charts, urinalysis, serum creatinine and osmolarity, diurnal and nocturnal electrolytes with fractional Na+ and K+ urinary excretion, and nocturnal (4 a.m.) plasma vasopressin. Creatinine electrolytes and osmolarity were measured in daytime (8 a.m. to 8 p.m.) and nighttime (8 p.m. to 8 a.m.) urine volumes. Patients were …

Malemedicine.medical_specialtyAdolescentendocrine system diseasesUrinalysisVasopressinsUrologymedia_common.quotation_subjectPopulationUrinary incontinenceUrologyUrinary incontinenceurologic and male genital diseasesUrinationDiagnosis DifferentialElectrolytesAdrenocorticotropic HormonePolyuriaEnuresisElectrolyteInternal medicineEnuresimedicineHumansEnuresis; Polyuria; Urinary incontinence; Vasopressin; Adolescent; Adrenocorticotropic Hormone; Calcium; Child; Circadian Rhythm; Creatinine; Deamino Arginine Vasopressin; Diagnosis Differential; Electrolytes; Enuresis; Female; Humans; Male; Polyuria; Vasopressins; UrologyDeamino Arginine VasopressinHypercalciuriaChildDesmopressineducationmedia_commoneducation.field_of_studymedicine.diagnostic_testPolyuriabusiness.industryEnuresismedicine.diseasefemale genital diseases and pregnancy complicationsCircadian RhythmEndocrinologyCreatinineCalciumFemalemedicine.symptombusinessVasopressinhormones hormone substitutes and hormone antagonistsHumanmedicine.drugJournal of Urology
researchProduct

A Comparison of Objective Physical Performance Tests and Future Mortality in the Elderly People.

2017

Background: Physical performance is an important predictor of mortality, but little is known on the comparative prognostic utility of different objective physical performance tests in community-dwelling older adults. We compared the prognostic usefulness of several objective physical performance tests on mortality, adjusting our analyses for potential confounders. Methods: Among 3,099 older community-dwelling participants included in the Progetto Veneto Anziani study, 2,096 were followed for a mean of 4.4 years. Physical performance tests measured were Short Physical Performance Battery (SPPB), 4-meter gait speed, chair stands time, leg extension and flexion, handgrip strength, and 6-Minute…

Malemedicine.medical_specialtyAgingMortality—Physical activity—Physical performancePoison controlPhysical examinationNOPhysical performance03 medical and health sciences0302 clinical medicinePredictive Value of TestsInjury prevention80 and overMedicineHumans030212 general & internal medicineMortalityMortality; Physical activity; Physical performance; Aged; Aged 80 and over; Female; Geriatric Assessment; Humans; Male; Mortality; Physical Examination; Predictive Value of Tests; Prognosis; Aging; Geriatrics and GerontologyGeriatric AssessmentPhysical ExaminationAgedMortality; Physical activity; Physical performanceAged 80 and overmedicine.diagnostic_testbusiness.industryPhysical activityConfoundingPrognosisConfidence intervalPreferred walking speedQuartilePredictive value of testsPhysical therapyFemaleGeriatrics and Gerontologybusinesshuman activities030217 neurology & neurosurgery
researchProduct

Evaluation of an alternative dosing regimenwith tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.

2007

AIM: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week, in men affected with erectile dysfunction (ED) in Italy. METHODS: Scheduled Use versus on demand Regimen Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged 18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment on demand or three times per week for 5-6 weeks. After a 1-week washout, patients were crossed over to the alternate regimen for 5-6 weeks. A treatment preference question was used to determine the preferred treatment regimen. International I…

Malemedicine.medical_specialtyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome; Nephrology; EndocrinologyPhosphodiesterase Inhibitorserectile dysfunctionUrologyerectile dysfunction; SURE study; on demand; three times per week; alternate; tadalafilon demandDrug Administration Schedulelaw.inventionSettore MED/24 - UrologiaEndocrinologyRandomized controlled triallawOn demandInternal medicinealternateMedicineHumansClinical significanceDosingthree times per weekErectile dysfunction SURE Study on demand three times per week alternate tadalafilSURE studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTadalafilSurgeryRegimenErectile dysfunctionTreatment OutcomeItalyNephrologyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcomebusinesstadalafilmedicine.drugCarbolines
researchProduct

Benign penile skin anomalies in children: a primer for pediatricians

2015

Abstract BACKGROUND: Abnormalities involving the skin coverage of the penis are difficult to define, but they can significantly alter penile appearance, and be a cause of parental concern. DATA SOURCES: The present review was based on a nonsystematic search of the English language medical literature using a combination of key words including "penile skin anomalies" and the specific names of the different conditions. RESULTS: Conditions were addressed in the following order, those mainly affecting the prepuce (phimosis, balanitis xerotica obliterans, balanitis, paraphimosis), those which alter penile configuration (inconspicuous penis and penile torsion), and lastly focal lesions (cysts, nev…

Malemedicine.medical_specialtyBalanitis xerotica obliteransPenile DiseasesforeskinPhysical examinationForeskinpenisPediatric surgerymedicinebalanitis xerotica obliteranHumansSex organGynecologyPenile Diseasemedicine.diagnostic_testbalanitis xerotica obliterans; foreskin; penis; phimosis; Humans; Infant; Infant Newborn; Male; Penile Diseases; Penis; Pediatrics Perinatology and Child Health; Medicine (all)business.industryMedicine (all)BalanitisInfant NewbornInfantbalanitis xerotica obliteransmedicine.diseaseNewbornDermatologyPeniphimosisbalanitis xerotica obliterans; foreskin; penis; phimosis; Humans; Infant; Infant Newborn; Male; Penile Diseases; Penismedicine.anatomical_structurePediatrics Perinatology and Child HealthbusinessParaphimosisPenisphimosiHuman
researchProduct

Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis

2016

Background: Serum uric acid (SUA) accounts for about 50% of extracellular antioxidant activity, suggesting that hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis. We aimed to meta-analyse data regarding bone mineral density (BMD), osteoporosis and fractures in people with higher SUA vs. lower SUA concentrations. Materials and methods: Two investigators conducted a literature search using PubMed and Scopus, without language restrictions. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used for BMD; risk ratios (RRs) and adjusted odds ratios (ORs) for cross-sectional data. Most possible adju…

Malemedicine.medical_specialtyBone densityClinical BiochemistryOsteoporosis030209 endocrinology & metabolismBone mineral density; fractures; hyperuricemia; osteoporosis; uric acid; Bone Density; Epidemiologic Methods; Female; Humans; Hyperuricemia; Male; Osteoporosis; Osteoporotic Fractures; Uric AcidhyperuricemiaBiochemistryBone remodelingNO03 medical and health sciences0302 clinical medicineBone mineral density; fractures; hyperuricemia; osteoporosis; uric aciduric acidBone DensityInternal medicinemedicineBone mineral densityHumansHyperuricemiaFemoral neck030203 arthritis & rheumatologyBone mineralbusiness.industryHazard ratioGeneral MedicineOdds ratiofracturesmedicine.diseaseosteoporosismedicine.anatomical_structureEndocrinologyFemalebusinessEpidemiologic MethodsOsteoporotic FracturesBone mineral density fractures hyperuricemia osteoporosis uric acid.
researchProduct

Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival esti…

2017

Abstract Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories…

Malemedicine.medical_specialtyCancer ResearchStage at diagnosiSurvivalConcordanceCancer registrieCancer registries ; Data quality ; Stage at diagnosis ; SurvivalSocio-culturaleReproducibility of ResultPredictive Value of TestCancer registries; Data quality; Stage at diagnosis; Survival; Data Accuracy; Europe; Female; Humans; Male; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Reproducibility of Results; Survival Analysis; Neoplasm Staging; Registries; Oncology; Cancer Research03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsNeoplasmsmedicineotorhinolaryngologic diseasesCancer registriesHumans030212 general & internal medicineRegistriesStage (cooking)Neoplasm MetastasisIntensive care medicineSurvival analysisCancer stagingNeoplasm Stagingbusiness.industryData qualityReproducibility of ResultsStage at diagnosismedicine.diseaseSurvival AnalysisCancer registryData AccuracyClinical trialNeoplasm MetastasiEuropeOncology030220 oncology & carcinogenesisData qualityNeoplasmFemaleSurvival AnalysibusinessHumanEuropean journal of cancer (Oxford, England : 1990)
researchProduct